RNXT

RenovoRx announced its first quarter 2026 financial results and business highlights conference call for May 14th, 2026, reporting $1.1 million in revenue for the full year 2025 from RenovoCath sales. An abstract supporting the TAMP therapy platform was accepted for presentation at the 2026 ASCO Annual Meeting, and clinical data was presented at the 2026 SIR Annual Scientific Meeting. The Phase III TIGeR-PaC trial surpassed 100 randomized patients, with enrollment completion anticipated by mid-2026 and final data in 2027. RenovoRx closed an oversubscribed $10 million at-market private placement in March 2026 and secured its first Notice of Allowance for a Japanese patent covering its RenovoCath device in April 2026. The company has reported continued commercial momentum with a growing number of U.S. cancer centers integrating RenovoCath into oncology treatment programs.